cardiac toxicity guidelines in older adults with hematological malignancies
Published 4 years ago • 62 plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
1:30
common cardiovascular toxicities in patients with hematological malignancies
-
1:03
managing cumulative cardiovascular toxicity associated with btk inhibitors
-
1:34
long-term surveillance for cardiac toxicities in patients with hl treated with chemotherapy
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:10
insights into the influence of cardiovascular toxicity risk on treatment selection in cll
-
1:40
challenges in monitoring for cardiotoxicity when treating patients with cll
-
0:38
pain management for patients with scd and thalassemia in lebanon
-
51:47
hypertension - mayo cardiology board review
-
56:19
hemodynamic cases - part 1
-
28:16
cardio-oncology what is the big picture, what drugs to use, tests to follow
-
1:20
the importance of cardio-oncology in cll
-
2:09
heart transplantation in attr amyloidosis
-
2:06
identification of genetic markers associated with ibrutinib-related cardiovascular toxicity
-
2:15
cardiac biomarkers for immune checkpoint inhibitor-related myocarditis in cancer patients
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
2:55
a model including cd49d expression to predict outcomes in patients with cll treated with ibrutinib
-
1:36
improve study update: safety and efficacy of venetoclax retreatment in r/r cll
-
1:07
cardiology updates for hematologists
-
1:21
cardiovascular adverse events following treatment with btk inhibitors in cll & mcl
-
1:21
trends in allosct for good-risk aml: a longitudinal study
-
3:47
cardio-oncology: a new medical field